Adaptive Biotechnologies Corporation will be presenting data from two studies employing Adaptive’s immune medicine platform to understand the T-cell response to SARS-CoV-2 infection at IDWeek 2021, which takes places virtually from September 29-October 3, 2021. T-cell responses are more durable and broader than antibody responses, recognizing many different parts of the SARS-CoV-2 virus, including both spike and non-spike proteins. By studying T-cell epitopes, the small parts of viruses to which cells bind that trigger the immune response, Adaptive can answer questions about T-cell contributions to vaccine efficacy and immunity to the SARS-CoV-2 virus and its variants, to uncover a better understanding of the full immune response. Examining the T-cell response has potential applications for clinical diagnosis and management, evaluation of protective immunity, and vaccine development and assessment. Adaptive will present new SARS-CoV-2 research at IDWeek that has implications for disease monitoring and vaccine development. A study evaluating the clinical performance of T-Detect™ COVID, the first T-cell-based test available in the U.S. to confirm recent or prior SARS-CoV-2 infection from whole blood samples, provides continued analysis and real-world evidence that confirms and extends previously published data regarding the durability of the detectable T-cell response, from 5 months up to nearly 12 months in a small number of evaluable patients after an initial positive Reverse Transcription (RT)-Polymerase Chain Reaction (PCR) test result. Similarly, a study employing Adaptive’s T-cell assay produced a quantitative picture of the T-cell response to SARS-CoV-2 and demonstrated the assay’s ability to distinguish a vaccine response from a natural infection based on the relative absence of T-cell receptors targeting non-spike antigens in vaccinated individuals.